Emerging drugs for small cell lung cancer – an update
Giulio Metro(University of Perugia), Lucio Crinò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Federico Cappuzzo(Ospedale di Livorno), Simona Duranti(Ospedale Sacro Cuore Don Calabria), Matthias Fischer(Goethe University Frankfurt)
Cited by 20
Related Papers
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
|JNCI Journal of the National Cancer Institute|2005|1.6k